Phase I trial of OMS 721 in volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics.

Trial Profile

Phase I trial of OMS 721 in volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2014

At a glance

  • Drugs OMS 721 (Primary) ; OMS 721 (Primary)
  • Indications Haemolytic uraemic syndrome; Thrombosis
  • Focus Adverse reactions
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 04 Mar 2014 Status changed from active, no longer recruiting to completed based on information in an Omeros Corporation media release. The company has submitted an IND for the phase II trial based on final data from this trial.
    • 04 Mar 2014 This study was conducted in the Netherlands under a Clinical Trial Application, according to an Omeros Corporation media release.
    • 03 Feb 2014 Top-line results reported in an Omeros Corporation media release following completion of dosing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top